Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

All News Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq
Other stock markets
 18:00:00 2024-05-14 EDT 		5-day change 1st Jan Change
13.35 USD 0.00% Intraday chart for Alvotech +0.45% +16.29%
04-30 Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals MT
04-30 Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alvotech S.A. Annual General Meeting to be held June 7, 2024
GL
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
AQ
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
GL
Alvotech : General Meeting Alvotech - Convening Notice (AGM 2024)
PU
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study For Its Proposed Golimumab Biosimilar
AQ
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
GL
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira
AQ
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA
AQ
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals
MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent
MT
Alvotech Announces U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira
CI
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
GL
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar
AQ
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
RE
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi
AQ
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study
MT
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
GL
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi
CI
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira
AQ
Sector Update: Health Care Stocks Advance Late Afternoon
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. News Alvotech
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW